Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models.

Ny L, Rizzo LY, Belgrano V, Karlsson J, Jespersen H, Carstam L, Bagge RO, Nilsson LM, Nilsson JA.

Ann Oncol. 2020 Feb;31(2):266-273. doi: 10.1016/j.annonc.2019.11.002. Epub 2020 Jan 3.

PMID:
31959343
2.

Surgery for gastrointestinal metastases of malignant melanoma - a retrospective exploratory study.

Holmberg CJ, Alwan G, Ny L, Olofsson Bagge R, Katsarelias D.

World J Surg Oncol. 2019 Jul 12;17(1):123. doi: 10.1186/s12957-019-1663-z.

3.

Real-world data on PD-1 inhibitor therapy in metastatic melanoma.

Arheden A, Skalenius J, Bjursten S, Stierner U, Ny L, Levin M, Jespersen H.

Acta Oncol. 2019 Jul;58(7):962-966. doi: 10.1080/0284186X.2019.1620966. Epub 2019 May 31.

PMID:
31151362
4.

A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden.

Isaksson K, Katsarelias D, Mikiver R, Carneiro A, Ny L, Olofsson Bagge R.

Ann Surg Oncol. 2019 Sep;26(9):2839-2845. doi: 10.1245/s10434-019-07448-y. Epub 2019 May 20.

5.

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.

Jespersen H, Olofsson Bagge R, Ullenhag G, Carneiro A, Helgadottir H, Ljuslinder I, Levin M, All-Eriksson C, Andersson B, Stierner U, Nilsson LM, Nilsson JA, Ny L.

BMC Cancer. 2019 May 2;19(1):415. doi: 10.1186/s12885-019-5623-3.

6.

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.

Forsberg EMV, Lindberg MF, Jespersen H, Alsén S, Bagge RO, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA.

Cancer Res. 2019 Mar 1;79(5):899-904. doi: 10.1158/0008-5472.CAN-18-3158. Epub 2019 Jan 8.

PMID:
30622115
7.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.

JAMA Oncol. 2019 Feb 1;5(2):187-194. doi: 10.1001/jamaoncol.2018.4514. Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271.

8.

Mouse avatars take off as cancer models.

Nilsson JA, Olofsson Bagge R, Ny L.

Nature. 2018 Oct;562(7726):192. doi: 10.1038/d41586-018-06982-1. No abstract available.

PMID:
30305752
9.

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma.

Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Bagge RO, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA.

Cell Death Dis. 2018 Jul 24;9(8):810. doi: 10.1038/s41419-018-0865-6.

10.

Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.

Jespersen H, Bjursten S, Ny L, Levin M.

Lancet Oncol. 2018 Jun;19(6):e327. doi: 10.1016/S1470-2045(18)30252-3. Epub 2018 Jun 1. No abstract available.

PMID:
29893264
11.

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma.

Veppil Muralidharan S, Osk Einarsdottir B, Bhadury J, Lindberg MF, Wu J, Campeau E, Olofsson Bagge R, Stierner U, Ny L, Nilsson LM, Nilsson JA.

Cell Death Dis. 2017 Dec 14;8(12):e3177. doi: 10.1038/cddis.2017.557.

12.

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.

Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA.

Nat Commun. 2017 Sep 27;8(1):707. doi: 10.1038/s41467-017-00786-z.

13.

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma.

Muralidharan SV, Einarsdottir BO, Bhadury J, Lindberg MF, Wu J, Campeau E, Bagge RO, Stierner U, Ny L, Nilsson LM, Nilsson JA.

Cell Death Dis. 2017 Aug 10;8(8):e2982. doi: 10.1038/cddis.2017.383. Erratum in: Cell Death Dis. 2017 Dec 14;8(12 ):e3177.

14.

[Great advances in the systemic treatment in malignant melanoma patients].

Ullenhag G, Hansson J, Ny L.

Lakartidningen. 2017 May 9;114. pii: ELM9. Swedish.

15.

Hyperbaric oxygen treatment reverses radiation induced pro-fibrotic and oxidative stress responses in a rat model.

Oscarsson N, Ny L, Mölne J, Lind F, Ricksten SE, Seeman-Lodding H, Giglio D.

Free Radic Biol Med. 2017 Feb;103:248-255. doi: 10.1016/j.freeradbiomed.2016.12.036. Epub 2016 Dec 27.

PMID:
28034833
16.

Adjuvant therapies for malignant melanoma.

Olofsson Bagge R, Ny L.

Br J Surg. 2016 Aug;103(9):1095-6. doi: 10.1002/bjs.10202. Epub 2016 Jun 1. No abstract available.

PMID:
27246114
17.

Downregulation of toll-like receptor 4 and IL-6 following irradiation of the rat urinary bladder.

Giglio D, Wasén C, Mölne J, Suchy D, Swanpalmer J, Jabonero Valbuena J, Tobin G, Ny L.

Clin Exp Pharmacol Physiol. 2016 Jul;43(7):698-705. doi: 10.1111/1440-1681.12583.

PMID:
27117224
18.

Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts.

Bhadury J, Einarsdottir BO, Podraza A, Bagge RO, Stierner U, Ny L, Dávila López M, Nilsson JA.

Oncotarget. 2016 Apr 26;7(17):23801-11. doi: 10.18632/oncotarget.8181.

19.

Plasminogen is a critical regulator of cutaneous wound healing.

Sulniute R, Shen Y, Guo YZ, Fallah M, Ahlskog N, Ny L, Rakhimova O, Broden J, Boija H, Moghaddam A, Li J, Wilczynska M, Ny T.

Thromb Haemost. 2016 May 2;115(5):1001-9. doi: 10.1160/TH15-08-0653. Epub 2016 Jan 21.

PMID:
26791370
20.

Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion.

Ben-Shabat I, Belgrano V, Ny L, Nilsson J, Lindnér P, Olofsson Bagge R.

Ann Surg Oncol. 2016 Apr;23(4):1327-34. doi: 10.1245/s10434-015-4982-5. Epub 2015 Dec 1.

PMID:
26628434
21.

Erratum to: Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.

Olofsson Bagge R, Ny L, All-Ericsson C, Sternby Eilard M, Rizell M, Cahlin C, Stierner U, Lönn U, Hansson J, Ljuslinder I, Lundgren L, Ullenhag G, Kiilgaard JF, Nilsson J, Lindnér P.

Trials. 2015 Aug 6;16:334. doi: 10.1186/s13063-015-0809-8. No abstract available.

22.

Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types.

Fredriksson NJ, Ny L, Nilsson JA, Larsson E.

Nat Genet. 2014 Dec;46(12):1258-63. doi: 10.1038/ng.3141. Epub 2014 Nov 10.

PMID:
25383969
23.

Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.

Einarsdottir BO, Bagge RO, Bhadury J, Jespersen H, Mattsson J, Nilsson LM, Truvé K, López MD, Naredi P, Nilsson O, Stierner U, Ny L, Nilsson JA.

Oncotarget. 2014 Oct 30;5(20):9609-18.

24.

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.

Olofsson R, Ny L, Eilard MS, Rizell M, Cahlin C, Stierner U, Lönn U, Hansson J, Ljuslinder I, Lundgren L, Ullenhag G, Kiilgaard JF, Nilsson J, Lindnér P.

Trials. 2014 Aug 9;15:317. doi: 10.1186/1745-6215-15-317. Erratum in: Trials. 2015;16:334. All-Ericsson, Charlotta [Added].

25.

Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain.

Krarup AL, Ny L, Gunnarsson J, Hvid-Jensen F, Zetterstrand S, Simrén M, Funch-Jensen P, Hansen MB, Drewes AM.

Scand J Gastroenterol. 2013 Mar;48(3):274-84. doi: 10.3109/00365521.2012.758769. Epub 2013 Jan 16.

PMID:
23320520
26.

Nitric oxide and endothelin-1 release after one-lung ventilation during thoracoabdominal esophagectomy.

Lund M, Ny L, Malmström RE, Lundberg JO, Öst Å, Björnstedt M, Lundell L, Tsai JA.

Dis Esophagus. 2013 Nov-Dec;26(8):853-8. doi: 10.1111/j.1442-2050.2012.01388.x. Epub 2012 Aug 7.

PMID:
22882570
27.

The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers.

Rohof WO, Lei A, Hirsch DP, Ny L, Astrand M, Hansen MB, Boeckxstaens GE.

Aliment Pharmacol Ther. 2012 May;35(10):1231-42. doi: 10.1111/j.1365-2036.2012.05081.x. Epub 2012 Apr 2.

28.

Bacterial flora of the human oral cavity, and the upper and lower esophagus.

Norder Grusell E, Dahlén G, Ruth M, Ny L, Quiding-Järbrink M, Bergquist H, Bove M.

Dis Esophagus. 2013 Jan;26(1):84-90. doi: 10.1111/j.1442-2050.2012.01328.x. Epub 2012 Mar 6.

PMID:
22394217
29.

Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain.

Krarup AL, Ny L, Astrand M, Bajor A, Hvid-Jensen F, Hansen MB, Simrén M, Funch-Jensen P, Drewes AM.

Aliment Pharmacol Ther. 2011 May;33(10):1113-22. doi: 10.1111/j.1365-2036.2011.04629.x. Epub 2011 Mar 16.

30.

Risk of clinically relevant bleeding in warfarin-treated patients--influence of SSRI treatment.

Wallerstedt SM, Gleerup H, Sundström A, Stigendal L, Ny L.

Pharmacoepidemiol Drug Saf. 2009 May;18(5):412-6. doi: 10.1002/pds.1737.

PMID:
19301238
31.

A magnetic resonance imaging study of intestinal dilation in Trypanosoma cruzi-infected mice deficient in nitric oxide synthase.

Ny L, Li H, Mukherjee S, Persson K, Holmqvist B, Zhao D, Shtutin V, Huang H, Weiss LM, Machado FS, Factor SM, Chan J, Tanowitz HB, Jelicks LA.

Am J Trop Med Hyg. 2008 Nov;79(5):760-7.

32.

Reporting of adverse drug reactions may be influenced by feedback to the reporting doctor.

Wallerstedt SM, Brunlöf G, Johansson ML, Tukukino C, Ny L.

Eur J Clin Pharmacol. 2007 May;63(5):505-8. Epub 2007 Mar 9.

PMID:
17347804
33.

Acid challenge to the human esophageal mucosa: effects on epithelial architecture in health and disease.

Bove M, Vieth M, Dombrowski F, Ny L, Ruth M, Lundell L.

Dig Dis Sci. 2005 Aug;50(8):1488-96.

PMID:
16110841
34.

Acid challenge to the esophageal mucosa: effects on local nitric oxide formation and its relation to epithelial functions.

Bove M, Vieth M, Casselbrant A, Ny L, Lundell L, Ruth M.

Dig Dis Sci. 2005 Apr;50(4):640-8.

PMID:
15844695
35.

Nitric oxide production in the sphenoidal sinus by the inducible and constitutive isozymes of nitric oxide synthase.

Petruson K, Stalfors J, Jacobsson KE, Ny L, Petruson B.

Rhinology. 2005 Mar;43(1):18-23.

PMID:
15844497
36.
37.

Effects of dietary nitrate on oesophageal motor function and gastro-oesophageal acid exposure in healthy volunteers and reflux patients.

Bove M, Lundell L, Ny L, Casselbrant A, Fändriks L, Pettersson A, Ruth M.

Digestion. 2003;68(1):49-56. Epub 2003 Aug 29.

PMID:
12949439
38.

Cholinergic nerves in human corpus cavernosum and spongiosum contain nitric oxide synthase and heme oxygenase.

Hedlund P, Ny L, Alm P, Andersson KE.

J Urol. 2000 Sep;164(3 Pt 1):868-75.

PMID:
10953170
39.

Impaired relaxation of stomach smooth muscle in mice lacking cyclic GMP-dependent protein kinase I.

Ny L, Pfeifer A, Aszòdi A, Ahmad M, Alm P, Hedlund P, Fässler R, Andersson KE.

Br J Pharmacol. 2000 Jan;129(2):395-401.

40.

Heme oxygenase-1, heme oxygenase-2 and biliverdin reductase in peripheral ganglia from rat, expression and plasticity.

Magnusson S, Ekström J, Elmér E, Kanje M, Ny L, Alm P.

Neuroscience. 2000;95(3):821-9.

PMID:
10670450
41.

The nitric oxide pathway in pig isolated calyceal smooth muscle.

Iselin CE, Ny L, Mastrangelo D, Felley-Bosco E, Larsson B, Alm P, Andersson KE.

Neurourol Urodyn. 1999;18(6):673-85.

PMID:
10529716
42.

Localization and activity of nitric oxide synthases in the gastrointestinal tract of Trypanosoma cruzi-infected mice.

Ny L, Persson K, Larsson B, Chan J, Weiss LM, Wittner M, Huang H, Tanowitz HB.

J Neuroimmunol. 1999 Sep 1;99(1):27-35.

PMID:
10496174
43.

Co-localization of carbon monoxide and nitric oxide synthesizing enzymes in the human urethral sphincter.

Ho KM, Ny L, McMurray G, Andersson KE, Brading AF, Noble JG.

J Urol. 1999 Jun;161(6):1968-72.

PMID:
10332482
44.

The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function.

Aszódi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L, Andersson KE, Kehrel B, Offermanns S, Fässler R.

EMBO J. 1999 Jan 4;18(1):37-48.

45.

Defective smooth muscle regulation in cGMP kinase I-deficient mice.

Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C, Wang GX, Korth M, Aszódi A, Andersson KE, Krombach F, Mayerhofer A, Ruth P, Fässler R, Hofmann F.

EMBO J. 1998 Jun 1;17(11):3045-51.

46.

The nitric oxide synthase/nitric oxide and heme oxygenase/carbon monoxide pathways in the human ureter.

Iselin CE, Ny L, Larsson B, Schaad NC, Alm P, Graber P, Morel DR, Andersson KE.

Eur Urol. 1998;33(2):214-21.

PMID:
9519368
47.

Mediators and mechanisms of relaxation in rabbit urethral smooth muscle.

Waldeck K, Ny L, Persson K, Andersson KE.

Br J Pharmacol. 1998 Feb;123(4):617-24.

48.

Nitric oxide synthase in the heterogeneous population of intramural striated muscle fibres of the human membranous urethral sphincter.

Ho KM, McMurray G, Brading AF, Noble JG, Ny L, Andersson KE.

J Urol. 1998 Mar;159(3):1091-6.

PMID:
9474237
49.

Neurotransmitter release evoked by alpha-latrotoxin in the smooth muscle of the female pig urethra.

Werkström V, Ny L, Persson K, Andersson KE.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Aug;356(2):151-8.

PMID:
9272719
50.

Morphological relations between haem oxygenases, NO-synthase and VIP in the canine and feline gastrointestinal tracts.

Ny L, Alm P, Larsson B, Andersson KE.

J Auton Nerv Syst. 1997 Jul 14;65(1):49-56.

PMID:
9258872

Supplemental Content

Support Center